182 related articles for article (PubMed ID: 33620658)
21. Epigenetic silencing of the dual-role signal mediator, ANGPTL4 in tumor tissues and its overexpression in the urothelial carcinoma microenvironment.
Hsieh HY; Jou YC; Tung CL; Tsai YS; Wang YH; Chi CL; Lin RI; Hung SK; Chuang YM; Wu SF; Li C; Shen CH; Chan MWY; Hsu CD
Oncogene; 2018 Feb; 37(5):673-686. PubMed ID: 29035390
[TBL] [Abstract][Full Text] [Related]
22. Immunohistochemical expressions of EMT markers in pan-RAS-pERK1/2-positive tumors improve diagnosis and prognosis assessment of non-muscle invasive bladder cancer and muscle invasive bladder cancer patients.
Tripathi K; Maurya N; Goel A; Singhai A; Garg M
Mol Cell Biochem; 2023 Jun; 478(6):1169-1190. PubMed ID: 36239855
[TBL] [Abstract][Full Text] [Related]
23. A systematic analysis on DNA methylation and the expression of both mRNA and microRNA in bladder cancer.
Zhu J; Jiang Z; Gao F; Hu X; Zhou L; Chen J; Luo H; Sun J; Wu S; Han Y; Yin G; Chen M; Han Z; Li X; Huang Y; Zhang W; Zhou F; Chen T; Fa P; Wang Y; Sun L; Leng H; Sun F; Liu Y; Ye M; Yang H; Cai Z; Gui Y; Zhang X
PLoS One; 2011; 6(11):e28223. PubMed ID: 22140553
[TBL] [Abstract][Full Text] [Related]
24.
Weyerer V; Eckstein M; Strissel PL; Wullweber A; Lange F; Tögel L; Geppert CI; Sikic D; Taubert H; Wach S; Wullich B; Hartmann A; Stoehr R; Giedl J
Genes (Basel); 2021 Feb; 12(2):. PubMed ID: 33562516
[TBL] [Abstract][Full Text] [Related]
25. Role of Ha-ras activation in superficial papillary pathway of urothelial tumor formation.
Zhang ZT; Pak J; Huang HY; Shapiro E; Sun TT; Pellicer A; Wu XR
Oncogene; 2001 Apr; 20(16):1973-80. PubMed ID: 11360181
[TBL] [Abstract][Full Text] [Related]
26. Positive Correlation between Matrix Metalloproteinases and Epithelial-to-Mesenchymal Transition and its Association with Clinical Outcome in Bladder Cancer Patients.
Singh R; Mandhani A; Agrawal V; Garg M
Cancer Microenviron; 2018 Jun; 11(1):23-39. PubMed ID: 29349669
[TBL] [Abstract][Full Text] [Related]
27. Activation of RAS family genes in urothelial carcinoma.
Boulalas I; Zaravinos A; Karyotis I; Delakas D; Spandidos DA
J Urol; 2009 May; 181(5):2312-9. PubMed ID: 19303097
[TBL] [Abstract][Full Text] [Related]
28. Transitional cell carcinomas and nonurothelial carcinomas of the urinary bladder differ in the promoter methylation status of the caveolin-1, hDAB2IP and p53 genes, but not in the global methylation of Alu elements.
Kunze E; Von Bonin F; Werner C; Wendt M; Schlott T
Int J Mol Med; 2006 Jan; 17(1):3-13. PubMed ID: 16328005
[TBL] [Abstract][Full Text] [Related]
29. Lack of decorin expression by human bladder cancer cells offers new tools in the therapy of urothelial malignancies.
Sainio A; Nyman M; Lund R; Vuorikoski S; Boström P; Laato M; Boström PJ; Järveläinen H
PLoS One; 2013; 8(10):e76190. PubMed ID: 24146840
[TBL] [Abstract][Full Text] [Related]
30. TAp73 expression and P1 promoter methylation, a potential marker for chemoresponsiveness to cisplatin therapy and survival in muscle-invasive bladder cancer (MIBC).
Bunch B; Krishnan N; Greenspan RD; Ramakrishnan S; Attwood K; Yan L; Qi Q; Wang D; Morrison C; Omilian A; Bshara W; Pili R; Trump DL; Johnson C; Woloszynska A
Cell Cycle; 2019 Sep; 18(17):2055-2066. PubMed ID: 31318640
[TBL] [Abstract][Full Text] [Related]
31. Clinical significance of protocadherin 8 (PCDH8) promoter methylation in non-muscle invasive bladder cancer.
Lin YL; Wang YL; Ma JG; Li WP
J Exp Clin Cancer Res; 2014 Aug; 33(1):68. PubMed ID: 25927589
[TBL] [Abstract][Full Text] [Related]
32. Hypomethylation of PlncRNA-1 promoter enhances bladder cancer progression through the miR-136-5p/Smad3 axis.
Kang W; Wang Q; Dai Y; Wang H; Wang M; Wang J; Zhang D; Sun P; Qi T; Jin X; Cui Z
Cell Death Dis; 2020 Dec; 11(12):1038. PubMed ID: 33288752
[TBL] [Abstract][Full Text] [Related]
33. [The Evaluation Value of Methylation Status of CpG Island of SFRP1 and LINE1 Gene Promoter Area in the Prognosis of Hepatocellular Carcinoma.].
Huang Y; Wei L; Sun AM; Zhao RC; Zhang J; Yang HT; Li B; Sun CJ; Ding XQ; Gao B; Zhong YQ; Qin Y
Sichuan Da Xue Xue Bao Yi Xue Ban; 2016 Nov; 47(6):883-888. PubMed ID: 28598118
[TBL] [Abstract][Full Text] [Related]
34. Correlation between messenger RNA expression and protein expression of immune checkpoint-associated molecules in bladder urothelial carcinoma: A retrospective study.
Le Goux C; Damotte D; Vacher S; Sibony M; Delongchamps NB; Schnitzler A; Terris B; Zerbib M; Bieche I; Pignot G
Urol Oncol; 2017 May; 35(5):257-263. PubMed ID: 28291636
[TBL] [Abstract][Full Text] [Related]
35. RUNX3 methylation as a predictor for disease progression in patients with non-muscle-invasive bladder cancer.
Yan C; Kim YW; Ha YS; Kim IY; Kim YJ; Yun SJ; Moon SK; Bae SC; Kim WJ
J Surg Oncol; 2012 Mar; 105(4):425-30. PubMed ID: 22311819
[TBL] [Abstract][Full Text] [Related]
36. Methylation pattern of oncogene HRAS gene promoter region and its clinical relevance to urocystic tumorigenesis.
Sun XF; Li L; Li XJ; Shen W
Mol Biol Rep; 2012 Aug; 39(8):8431-7. PubMed ID: 22707223
[TBL] [Abstract][Full Text] [Related]
37. Non-CpG island promoter hypomethylation and miR-149 regulate the expression of SRPX2 in colorectal cancer.
Øster B; Linnet L; Christensen LL; Thorsen K; Ongen H; Dermitzakis ET; Sandoval J; Moran S; Esteller M; Hansen TF; Lamy P; ; Laurberg S; Ørntoft TF; Andersen CL
Int J Cancer; 2013 May; 132(10):2303-15. PubMed ID: 23115050
[TBL] [Abstract][Full Text] [Related]
38. Oxidative stress induces hypomethylation of LINE-1 and hypermethylation of the RUNX3 promoter in a bladder cancer cell line.
Wongpaiboonwattana W; Tosukhowong P; Dissayabutra T; Mutirangura A; Boonla C
Asian Pac J Cancer Prev; 2013; 14(6):3773-8. PubMed ID: 23886181
[TBL] [Abstract][Full Text] [Related]
39. MDR1 gene overexpression and altered degree of methylation at the promoter region in bladder cancer during chemotherapeutic treatment.
Tada Y; Wada M; Kuroiwa K; Kinugawa N; Harada T; Nagayama J; Nakagawa M; Naito S; Kuwano M
Clin Cancer Res; 2000 Dec; 6(12):4618-27. PubMed ID: 11156211
[TBL] [Abstract][Full Text] [Related]
40. Morphologic and genomic characterization of urothelial to sarcomatoid transition in muscle-invasive bladder cancer.
Genitsch V; Kollár A; Vandekerkhove G; Blarer J; Furrer M; Annala M; Herberts C; Pycha A; de Jong JJ; Liu Y; Krentel F; Davicioni E; Gibb EA; Kruithof-de Julio M; Wyatt AW; Seiler R
Urol Oncol; 2019 Nov; 37(11):826-836. PubMed ID: 31585777
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
